00:00
27:54
Dr. Jacob Corn, ACT’s 2015 Plenary Lecturer, is a Professor of Genome Biology at the Swiss Federal Institute of Technology in Zurich. The Corn Laboratory develops next-generation genome editing and regulation technologies for fundamental biological discovery and to develop potential therapies for human genetic diseases. In this episode, he will describe how CRISPR may impact the treatment of rare diseases, while providing context for drug safety evaluation. Potential applications and ethical considerations for livestock and human organ development will be covered, in addition to primary concerns about the future of CRISPR. Dr. Corn will share what he considers to be the key milestones, greatest advancements, and unforeseen surprises in the evolution of CRISPR technologies.
Dr. Jacob Corn, ACT’s 2015 Plenary Lecturer, is a Professor of Genome Biology at the Swiss Federal Institute of Technology in Zurich. The Corn Laboratory develops next-generation genome editing and regulation technologies for fundamental biological discovery and to develop potential therapies for human genetic diseases. In this episode, he will describe how CRISPR may impact the treatment of rare diseases, while providing context for drug safety evaluation. Potential applications and ethical considerations for livestock and human organ development will be covered, in addition to primary concerns about the future of CRISPR. Dr. Corn will share what he considers to be the key milestones, greatest advancements, and unforeseen surprises in the evolution of CRISPR technologies. read more read less

4 years ago #act, #bio, #college, #corn, #crisper, #discovery, #editing, #engineering, #gene, #genetic, #genome, #medical, #modification, #podcast, #sequence, #therapies, #tox, #toxchats